Funding for this research was provided by:
Received: 29 September 2020
Accepted: 26 July 2021
First Online: 11 August 2021
: Ethics approval was granted by the Nova Scotia Health Authority Research Ethics Board (NSHA REB ROMEO FILE #: 100240). All patient participants provided written informed consent.
: Not applicable.
: J. C. reports grants from Bayer Inc. during the conduct of the study and personal fees from Bayer, Servier, and HLS Therapeutic, outside the submitted work. R.P. reports grants from Bayer and Pfizer during the conduct of the study. J.M.K. reports other fees from Merck Canada, Bayer, and Pfizer outside the submitted work. A.C. and S.H.C. are employees of Bayer Inc. J.N.W. reports personal fees from Nova Scotia Health Authority during the conduct of the study. All other authors declare no competing interests.